(0.17%) 5 108.74 points
(0.14%) 38 292 points
(0.22%) 15 963 points
(-1.14%) $82.89
(4.73%) $2.01
(0.11%) $2 349.80
(0.07%) $27.56
(4.11%) $960.00
(-0.18%) $0.933
(-0.27%) $10.99
(-0.45%) $0.797
(1.73%) $93.46
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally...
Stats | |
---|---|
本日の出来高 | 118 380 |
平均出来高 | 362 209 |
時価総額 | 85.84M |
EPS | $0 ( 2024-03-14 ) |
次の収益日 | ( $-0.0200 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 13.06 |
ATR14 | $0.00600 (0.51%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Bashan Dror | Buy | 263 960 | Common Stock |
2023-10-19 | Bashan Dror | Buy | 16 129 | Common Stock |
2023-10-19 | Bashan Dror | Buy | 48 387 | Common Stock |
2023-09-29 | Boudes Pol F | Buy | 61 676 | Stock Options (Right to Buy) |
2023-09-29 | Melincoff Gwen A | Buy | 61 676 | Stock Options (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 87 transactions |
Buy: 22 496 164 | Sell: 34 117 800 |
ボリューム 相関
Protalix Biotherapeutics 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Protalix Biotherapeutics 相関 - 通貨/商品
Protalix Biotherapeutics 財務諸表
Annual | 2023 |
収益: | $65.49M |
総利益: | $42.51M (64.91 %) |
EPS: | $0.120 |
FY | 2023 |
収益: | $65.49M |
総利益: | $42.51M (64.91 %) |
EPS: | $0.120 |
FY | 2022 |
収益: | $47.64M |
総利益: | $28.05M (58.87 %) |
EPS: | $-0.310 |
FY | 2021 |
収益: | $38.35M |
総利益: | $22.00M (57.37 %) |
EPS: | $-0.620 |
Financial Reports:
No articles found.
Protalix Biotherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。